Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • General Shareholders Meeting
  • Board of Directors
  • Board Committees
  • Shareholder Agreements
  • Annual Corporate Governance Reports
  • Annual Director Remuneration Reports

Corporate Governance

  • General Shareholders Meeting
  • Board of Directors
  • Board Committees
  • Shareholder Agreements
  • Annual Corporate Governance Reports
  • Annual Director Remuneration Reports

Breadcrumb

  1. Home
  2. Investors
  3. Corporate Governance
  4. Board of Directors

Board of Directors

  • Carlos Buesa

    President (Executive Director)
  • Manuel López-Figueroa

    Board Member (Independent Director)
  • Luis Sánchez Quintana

    Board Member (Independent Director)
  • Konstantinos Alataris

    Board Member (Independent Director)
  • Montserrat Vendrell

    Board Member (Independent Director)
  • Pierre Beaurang

    Board Member (Independent Director)
Regulations of the Board of Directors
Regulations of the Board of Directors (Spanish)
Oryzon Extraordinary General Meeting of Shareholders, 15 December 2026Oryzon Extraordinary General Meeting of Shareholders, 15 December 2026
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel